Target intelligence / Profile preview

Probable ATP-dependent RNA helicase DDX46 (DDX46)

Target
DDX46
Molecular classification
Enzyme, RNA helicase, DEAD-box protein family, Component of spliceosome (17S U2 snRNP complex)
01

Overview

Probable ATP-dependent RNA helicase DDX46 (DDX46) is an enzyme and member of the DEAD-box protein family, characterized by the conserved Asp-Glu-Ala-Asp (DEAD) motif[1][7]. It functions as a putative RNA helicase involved in pre-mRNA splicing by facilitating the unwinding of RNA secondary structures and is an essential component of the 17S U2 small nuclear ribonucleoprotein (snRNP) complex in the spliceosome[1][6]. DDX46 plays a key role in post-transcriptional regulation of gene expression, cell proliferation, and development, and has been implicated in modulation of innate immune responses by regulating nuclear export of antiviral transcripts[2]. Abnormal DDX46 expression correlates with tumorigenesis and poor prognosis in several cancers, making it a potential target for anti-cancer therapy[4][9]. However, no direct DDX46-targeting drugs are currently available.

Other names
DEAD box protein 46DEAD (Asp-Glu-Ala-Asp) box polypeptide 46KIAA0801FLJ25329PRPF5 homologPrp5Prp5-like DEAD-box proteinRNA helicase DDX46
02

Mechanism of action

Not applicable (no approved or investigational drugs directly targeting DDX46 are currently in development or clinical use; in experimental settings, knockdown or inhibition of DDX46 reduces tumorigenicity and modulates immune signaling)

03

Biological functions

Pre-mRNA splicingRNA secondary structure unwindingRegulation of gene expressionRibosome and spliceosome assemblyCell proliferationApoptosis regulationInnate immune response regulation
04

Disease associations

Cancer (colorectal, esophageal, gastric, osteosarcoma, cutaneous squamous cell carcinoma)TumorigenesisImmune response regulation (antiviral immunity suppression)
05

Safety considerations

As DDX46 is essential for normal pre-mRNA splicing and basic cellular RNA metabolism, therapeutic targeting carries a theoretical risk of widespread cellular toxicity, impaired development, and dysregulation of critical cellular processes (such as hematopoiesis and organogenesis)
06

Interacting drugs

None specifically reported for direct inhibition or modulation of DDX46 as of current literature; DDX46 is considered a promising therapeutic target in cancer, but no drugs are currently established
07

Biomarkers

Elevated DDX46 expression serves as a potential biomarker for cancer progression and poor prognosis in several tumor types, especially colorectal, esophageal, and gastric cancers

Beyond the preview

Go deeper on Probable ATP-dependent RNA helicase DDX46 (DDX46).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Probable ATP-dependent RNA helicase DDX46 (DDX46).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call